Promise Bio
About Promise Bio
The startup operates an artificial intelligence-based healthcare platform that utilizes biomarker discovery technology to create personalized treatment plans for chronic diseases. This approach enables patients to access affordable and effective care, improving their overall health outcomes.
```xml <problem> Current methods for predicting treatment response and stratifying patients with autoimmune diseases often lack the scalability and accuracy needed for personalized medicine. Traditional proteomic analyses may overlook critical post-translational modifications (PTMs) that regulate protein activity and function, hindering a comprehensive understanding of disease mechanisms. </problem> <solution> PromiseBio offers a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data to uncover hidden insights into autoimmune diseases. By studying post-translational modifications (PTMs), the platform provides a comprehensive view of disease mechanisms and captures the regulated proteome. The platform leverages explainable AI and clinically-oriented algorithms to provide high-impact recommendations for treatment selection, early assessment of response, and disease monitoring. PromiseBio's approach enables true scalability in response prediction and patient stratification, facilitating precision medicine for autoimmune diseases. </solution> <features> - Cloud-based AI platform for epiproteomic analyses - Unbiased approach exploring a broad range of the PTM landscape - Integration of chemical knowledge, statistics, and advanced algorithms - Explainable AI and clinically-oriented algorithms for high-impact recommendations - Leveraging of standard mass-spectrometry data without chemical enrichment - Identification of biomarkers for autoimmune diseases - Prediction of treatment response and patient stratification </features> <target_audience> PromiseBio targets pharmaceutical companies seeking to boost drug development through biomarker discovery and patient selection, as well as clinicians aiming to enable precision medicine through improved treatment selection and disease monitoring for patients with autoimmune diseases. </target_audience> ```
What does Promise Bio do?
The startup operates an artificial intelligence-based healthcare platform that utilizes biomarker discovery technology to create personalized treatment plans for chronic diseases. This approach enables patients to access affordable and effective care, improving their overall health outcomes.
Where is Promise Bio located?
Promise Bio is based in Tel Aviv, Israel.
When was Promise Bio founded?
Promise Bio was founded in 2023.
How much funding has Promise Bio raised?
Promise Bio has raised 16600000.
- Location
- Tel Aviv, Israel
- Founded
- 2023
- Funding
- 16600000
- Employees
- 10 employees
- Major Investors
- Israel Innovation Authority